SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing heightened volatility as the CME implements multiple margin requirement hikes, fueling intense community debate over market manipulation. Many perceive these actions as a concerted effort to suppress prices and liquidate leveraged positions, especially with reported disparities between paper and physical silver values globally. Despite calls of a "rigged game" and comparisons to past crashes, a strong bullish contingent anticipates a significant long-term rally driven by robust industrial demand and ongoing concerns about supply.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to high anticipation for upcoming FDA decisions regarding AXS-05 for Alzheimer's agitation and AXS-12 for narcolepsy, with the community optimistic about potential approvals. This regulatory excitement is complemented by strong, consistent prescription growth and expanding market access for its major depressive disorder treatment, Auvelity. Investors are keenly focused on these catalysts and the company's broader CNS pipeline, despite some impatience with communication around timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Tenon Medical, Inc. surged more than 280% on Tuesday, marking their best day ever, with the nano-cap medical device firm's retail following&nbsp;on Stocktwits surging the most among healthcare stocks after a key regulatory approval.During after-hours trading on Monday, Tenon said that the U.S. Food and Drug Administration had cleared its Catamaran SI Joint Fusion System for expanded use in augmenting thoracolumbar fusion."With this approval, the Catamaran is now indicated to treat the SI [sacroiliac] joint as either a stand-alone treatment or to augment a spinal fusion," the company said in a statement.Tenon's Catamaran system is designed as a minimally invasive solution for stabilizing the joint where the lower spine and pelvic bone meet. It uses a single titanium implant to secure the joint by passing through key bone structures.&nbsp;On Stocktwits, Tenon gained 25% more followers from a day ago, as sentiment turned even more 'extremely bullish' while message volume soared by 813%.One user said if the stock breaks the $5 level again, it "will go to $7+ fast. Shorts will have to cover."<stembedurl>https://stocktwits.com/BullsEye2000/message/609170603</stembedurl>However, Tenon shares fell more than 5% in Tuesday's extended trading after the company announced a $1.5 million registered direct offering to a healthcare-focused institutional investor.&nbsp;Under the agreement, Tenon will issue 733,500 shares at $2 each and an equal number of warrants exercisable at the same price.&nbsp;The company expects to close the offering on Wednesday, and the proceeds will be used for working capital and general corporate purposes.However, several optimistic retail watchers were still not rankled. One user said, "Everyone's panicking over the offering, but it was a direct offering so it got them secured cash to move forward without diluting the base rapidly."<stembedurl>https://stocktwits.com/FLCaptain/message/609231053</stembedurl>Tenon's stock has gained a whopping 93% so far this year. The sole analyst covering it on Wall Street rates it a 'strong buy,' according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tenon Medical Stock Rockets Nearly 4x, Leads Retail Follower Surge In Healthcare: What's Driving The Hype?

The medical device company said that the FDA had cleared its Catamaran SI Joint Fusion System for expanded use in augmenting thoracolumbar fusion.

Equity

Shares of surgical solutions firm Tenon Medical, Inc (TNON) shot up over 145% on Friday after the company announced the pricing of its public offering of shares and warrants in order to meet a Nasdaq minimum float requirement.The firm had earlier received a letter from Nasdaq stating that it did not meet the “minimum 500,000 publicly held shares requirement.”&nbsp;The compliance issue followed Tenon Medical common stock’s 1-for-8 reverse split which reduced the firm’s outstanding common stock from a little over 4.08 million shares to 510,221 shares outstanding on a post-reverse split basis. Only 490,364 of such shares qualified as publicly held shares for purposes of the minimum float requirement, the firm said in an SEC filing.Nasdaq had provided time till October 24, 2024 for the firm to come up with a plan to regain the compliance. Tenon, however, stated that it expects to regain compliance with the minimum float requirement in September itself.On Friday, the company announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock and warrants to purchase an equal number of shares at a combined offering price of $3.68 per share.Tenon expects to receive aggregate gross proceeds of approximately $4.5 million, assuming no exercise of the warrants. The firm said that the warrants will have an exercise price of $3.55 per share and will be exercisable immediately. They will expire five years from the issuance date, Tenon said.The offering is expected to close on Sept. 16, 2024, with Tenon intending to use the net proceeds for commercial activity, working capital and general corporate purposes.In early September, the firm entered into a securities purchase agreement with certain investors to offer a total of 86,454 Series B preferred stock and warrants to purchase 16,214 shares of common stock at an exercise price equal to $4.2756 per share for an aggregate offering price of $550,000.Tenon Medical’s shares have gained more than 87% over the last month, with the firm attracting investor eyeballs in the wake of the compliance developments.&nbsp;As a result, Stocktwits message volume shot up a whopping 64,900% during the same period as investors continued to discuss the fate of the stock.Some investors, however, are advising to maintain caution.<stembedurl>https://stocktwits.com/Spacerobot/message/585993209</stembedurl>Also See: <a href="https://stocktwits.com/news/markets/equity/united-airlines-to-offer-free-inflight-wifi-using-spacexs-starlink/c7zC6s5R5e">United Airlines To Offer Free Inflight Wi-Fi From SpaceX’s Starlink: Retail Sentiment Gets A Boost</a>

Nasdaq had provided time till October 24, 2024 for Tenon Medical to come up with a plan to regain the compliance.

Tenon Stock Skyrockets 145% After Public Offering To Meet Nasdaq Rules: Retail Chatter Goes Through The Roof

The firm had earlier received a letter from Nasdaq stating that it did not meet the “minimum 500,000 publicly held shares requirement.”

Tenon Medical, Inc. is a medical device company, which engages in the development of a minimally invasive approach to the sacroiliac joint (SI joint) using a single titanium implant for treatment of the most common types of SI Joint disorders. The company was founded by Richard Ferrari and Richard Ginn on June 19, 2012 and is headquartered in Los Gatos, CA.

TNON
Tenon Medical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNON News

TNONTenon Medical Inc